Evidence map›Paper›PMID 41683852›Full record

ReviewInternational journal of molecular sciences2026

Benzodiazepine Dependence: Clinical and Molecular Aspects, Preventive Strategies and Therapeutic Approaches.

Francisco Navarrete, Marta Marín-Mayor, Lorena Martínez-Hostyn, Gabriel Rubio, Jorge Manzanares

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Isothiocyanate-Rich Essential Oil ofPlants (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Francisco NavarreteInstituto de Neurociencias, Universidad Miguel Hernández-CSIC, Avda. de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain.ORCID 0000-0003-1251-6357
Marta Marín-MayorRed de Investigación en Atención Primaria de Adicciones, Instituto de Salud Carlos III, MICINN and FEDER, 28029 Madrid, Spain.ORCID 0000-0001-8335-9382
Lorena Martínez-HostynInstituto de Neurociencias, Universidad Miguel Hernández-CSIC, Avda. de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain.
Gabriel RubioRed de Investigación en Atención Primaria de Adicciones, Instituto de Salud Carlos III, MICINN and FEDER, 28029 Madrid, Spain.ORCID 0000-0002-1171-1508
Jorge ManzanaresInstituto de Neurociencias, Universidad Miguel Hernández-CSIC, Avda. de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain.ORCID 0000-0002-4681-1533

Funding

Centro de Excelencia Severo Ochoa CEX2021-001165-SInstituto de Investigación Biomedica y Sanitaria de Alicante (ISABIAL) N/APlan Nacional Sobre Drogas (PNSD), Ministerio de Sanidad 2023I026Red de Investigación en Atención Primaria de Adicciones (RIAPAd), Instituto de Salud Carlos III (ISCIII) RD24/0003/0002Red de Investigación en Atención Primaria de Adicciones (RIAPAd), Instituto de Salud Carlos III (ISCIII) RD24/0003/0009
6 · The paper itself

Abstract

Benzodiazepines (BZDs) are globally prevalent psychotropic substances valued for their anxiolytic, hypnotic, anticonvulsant, and myorelaxant properties. Pharmacologically, they act as positive allosteric modulators of the ionotropic GABA

Indexed as

BenzodiazepinesSubstance-Related DisordersAnimalsHumansReceptors, GABA-ABenzodiazepinesReceptors, GABA-Abenzodiazepineclinical indicationsdependencemolecular neurobiologypharmacologypreventiontherapeutic strategiestolerancewithdrawal

Identifiers

PMID41683852
PMCPMC12898709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.